Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,506 shares of the medical research company’s stock after buying an additional 362 shares during the quarter. Everett Harris & Co. CA’s holdings in Thermo Fisher Scientific were worth $7,546,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Legacy Investment Solutions LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter worth $26,000. Peterson Financial Group Inc. acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $27,000. Missouri Trust & Investment Co acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. Endeavor Private Wealth Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Finally, Decker Retirement Planning Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $43,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $15,859,540. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $598.40 on Friday. The stock has a market capitalization of $228.89 billion, a price-to-earnings ratio of 37.52, a price-to-earnings-growth ratio of 3.89 and a beta of 0.76. The stock’s fifty day simple moving average is $539.66 and its 200-day simple moving average is $570.59. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

TMO has been the subject of a number of research analyst reports. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday. Royal Bank of Canada reduced their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $655.64.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.